Clinical Trial Update: A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

This document reports on a Phase II clinical trial evaluating the combination of glofitamab with polatuzumab-R-CHP for high-risk diffuse large B-cell lymphoma, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Glofitamab (glofitamab)
• PREDNISONE (Prednisone)
• Polivy (polatuzumab vedotin) (polatuzumab vedotin)
• Rituxan (rituximab)

Snippet

Sponsor: Jennifer Crombie, MD | Conditions: Lymphoma, Lymphoma, Large B-Cell, Diffuse | Phase 2 | Status: RECRUITING